急性髓系白血病患者HtrA2基因、Set基因表达与疗效和预后的关系研究

摘要 目的：探讨急性髓系白血病（AML）患者HtrA2基因、Set基因表达与疗效和预后的关系。方法：选择2017年6月~2019年6月来我院进行治疗的90例病历资料完整的初诊为AML患者作为本次研究对象，作为AML组，另选取同时期来我院进行健康体检的90例志愿者作为对照组。检测HtrA2基因、Set基因在两组受试者外周血中的表达；分析HtrA2基因、Set基因的表达与AML患者年龄、性别、白细胞计数、NCCN预后分型和疗效的关系。结果：HtrA2基因在AML组中表达水平低于对照组，Set基因在AML组中表达水平高于对照组（P<0.05）。HtrA2基因的表达和年龄、性别、白细胞计数无关（P>0.05）；Set基因的表达和年龄、性别无关（P>0.05），与白细胞计数有关（P<0.05）。HtrA2基因在NCCN不同的预后分组中的表达差异无统计学意义（P>0.05）；Set基因在NCCN不同的预后分组中的表达差异有统计学意义（P<0.05）。HtrA2基因和Set基因在不同疗效患者中的表达差异有统计学意义（P<0.05）。结论：AML患者HtrA2基因表达下降，Set基因表达升高，Set基因和HtrA2基因具有评估AML疗效的潜力，Set基因可辅助评估AML患者的预后。

Study on the Relationship between the Expression of HtrA2 Gene and Set Gene and the Efficacy and Prognosis of Patients with Acute Myeloid Leukemia

ABSTRACT Objective: To investigate the relationship between the expression of HtrA2 gene and Set gene in patients with acute myeloid leukemia (AML) and the efficacy and prognosis. Methods: The clinical data 90 newly diagnosed patients with AML complete medical records treated in our hospital from June 2017 to June 2019 were selected as the subjects of this study, taken as AMI group. 90 healthy volunteers in our hospital were taken as the control group at the same time. The expression of HtrA2 gene and Set gene in peripheral blood of the two groups were detected. The relationship between the expression of HtrA2 gene and Set gene and age, gender, white blood cell count, prognosis classification of NCCN and efficacy. Results: The expression level of HtrA2 gene in AML group was lower than that in control group, while the expression level of set gene in AML group was higher than that in control group (P<0.05). There were no significant correlation between the expression of HtrA2 gene and age, gender, and white blood cell count (P>0.05);There were no significant correlation between the expression of Set gene and age, gender (P>0.05), while it was related to white blood cell count (P<0.05). There was no significant difference in expression of HtrA2 gene in different prognostic groups of NCCN (P>0.05). The expression of Set gene in different prognostic groups of NCCN was significantly different (P<0.05). There were significant difference in the expression of HtrA2 gene and Set gene in patients with different efficacy (P<0.05). Conclusion: In patients with AML, HtrA2 gene expression is decreased, and Set gene expression is increased. Set gene and HtrA2 gene have the potential to evaluate the curative effect of AML. Set gene can help to evaluate the prognosis of AML patients.